Meeting NewsVideo

VIDEO: Endoscopic therapy for GERD in the ‘best position it’s ever been’

SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Ronnie Fass, MD, FACG, medical director of the digestive health center at MetroHealth Medical Center in Cleveland, discusses endoscopic therapies for patients with GERD.

Fass presented the “pro” argument in the session titled, “Do endoscopic anti-reflux therapies have a tole in 2019?”

Endoscopic therapy for gastroesophageal reflux disease is now in the best position it’s ever been,” Fass told Healio Gastroenterology and Liver Disease. “Because of the simple reason that less patients are now interested in long-term treatment with proton pump inhibitors.”

In addition to adverse events, Fass said patients are weary of PPIs because of potential dependency issues, as well as the possibility of being on the drug for their entire lives. Additionally, fewer patients are interested in surgical therapies.

While these factors put endoscopic therapies in a good position, Fass said patients must still fit certain requirements, including the right acid levels, lower-grade erosive esophagitis and have at least some response to PPIs.

“This type of procedure requires expertise,” Fass said. “They should only be done by those that are very well trained, have all the resources that are required to perform the endoscopic therapy and they do a certain number of them on a regular basis.”

Disclosures: Fass reports consulting and being on the speakers bureau for Mederi Therapeutics.

SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Ronnie Fass, MD, FACG, medical director of the digestive health center at MetroHealth Medical Center in Cleveland, discusses endoscopic therapies for patients with GERD.

Fass presented the “pro” argument in the session titled, “Do endoscopic anti-reflux therapies have a tole in 2019?”

Endoscopic therapy for gastroesophageal reflux disease is now in the best position it’s ever been,” Fass told Healio Gastroenterology and Liver Disease. “Because of the simple reason that less patients are now interested in long-term treatment with proton pump inhibitors.”

In addition to adverse events, Fass said patients are weary of PPIs because of potential dependency issues, as well as the possibility of being on the drug for their entire lives. Additionally, fewer patients are interested in surgical therapies.

While these factors put endoscopic therapies in a good position, Fass said patients must still fit certain requirements, including the right acid levels, lower-grade erosive esophagitis and have at least some response to PPIs.

“This type of procedure requires expertise,” Fass said. “They should only be done by those that are very well trained, have all the resources that are required to perform the endoscopic therapy and they do a certain number of them on a regular basis.”

Disclosures: Fass reports consulting and being on the speakers bureau for Mederi Therapeutics.

    See more from American College of Gastroenterology Annual Meeting